Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia

Lung Cancer

Volumn 64, Issue 3, 2009, Pages 308-313

  Lee, Christopher W ^a   Murray, Nevin ^a   Anderson, Helen ^a   Rao, Sanjay C ^a   Bishop, Winston ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Cohort study; Gemcitabine; Mesothelioma; Pemetrexed; Platinum analogs

Indexed keywords

CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; FOLIC ACID; GEMCITABINE; NAVELBINE; OXALIPLATIN; PEMETREXED;

ADULT; AGED; ARTICLE; CANADA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENDER; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRITISH COLUMBIA; CISPLATIN; CLINICAL TRIALS, PHASE II AS TOPIC; COHORT STUDIES; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PLATINUM; PLEURAL NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67349198885     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.09.008     Document Type: Article

References (26)

1. Ellis P., Davies A., Evans W., Haynes A., and Lloyd N. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 1 6 (2006) 591-601
2. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax 62 Suppl 2 (2007) ii1-ii9
3. Vogelzang N., Rusthoven J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
4. van Meerbeeck J., Gaafar R., Manegold C., Van Klaveren R., Van Marck E., Vincent M., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23 (2005) 6881-6889
5. Byrne M., Davidson J., Musk A., Dewar J., van Hazel G., Buck M., et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17 1 (1999) 25-30
6. van Haarst J., Baas P., Manegold C., Schouwink J., Burgers J., de Bruin H., et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86 3 (2002) 342-345
7. Nowak A., Byrne M., Williamson R., Ryan G., Segal A., Fielding D., et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87 5 (2002) 491-496
8. Utkan G., Büyükçelik A., Yalçin B., Akbulut H., Demirkazik A., Dinçol D., et al. Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma. Lung Cancer 53 3 (2006) 367-374
9. Ardizzoni A., Boni L., Tiseo M., Fossella F., Schiller J., Paesmans M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99 11 (2007) 847-857
10. Hughes A., Calvert P., Azzabi A., Plummer R., Johnson R., Rusthoven J., et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20 16 (2002) 3533-3544
11. Ceresoli G., Zucali P., Favaretto A., Grossi F., Bidoli P., Del Conte G., et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24 9 (2006) 1443-1448
12. Favaretto A., Aversa S., Paccagnella A., Manzini Vde P., Palmisano V., Oniga F., et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 97 11 (2003) 2791-2797
13. Rusch V. A proposed new international TNM staging system for malignant pleural mesothelioma From the International Mesothelioma Interest Group. Chest 108 4 (1995) 1122-1128
14. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 282 (1958) 457-481
15. Peto R., and Peto J. Asymptotically Efficient Rank Invariant Test Procedures. J R Stat Soc Ser A 135 2 (1972) 185-207
16. Curran D., Sahmoud T., Therasse P., van Meerbeeck J., Postmus P., and Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16 1 (1998) 145-152
17. Scagliotti G., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26 21 (2008) 3543-3551
18. Santoro A., O'Brien M., Stahel R., Nackaerts K., Baas P., Karthaus M., et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 3 7 (2008) 756-763
19. Manegold C., Symanowski J., Gatzemeier U., Reck M., von Pawel J., Kortsik C., et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 16 6 (2005) 923-927
20. Steele J. Prognostic factors for mesothelioma. Hematol Oncol Clin North Am 19 6 (2005) 1041-1052
21. Steele J., Klabatsa A., Fennell D., Palläska A., Sheaff M., Evans M., et al. Prognostic factors in mesothelioma. Lung Cancer 49 Suppl 1 (2005) S49-S52
22. Edwards J., Abrams K., Leverment J., Spyt T., Waller D., and O'Byrne K. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55 9 (2000) 731-735
23. Fennell D., Parmar A., Shamash J., Evans M., Sheaff M., Sylvester R., et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 23 1 (2005) 184-189
24. Chapman A., Mulrennan S., Ladd B., and Muers M. Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax 63 5 (2008) 435-439
25. Delbaldo C., Michiels S., Syz N., Soria J., Le Chevalier T., and Pignon J. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer. JAMA 292 4 (2004) 470-484
26. Lee A., Raz D., He B., and Jablons D. Update on the molecular biology of malignant mesothelioma. Cancer 109 8 (2007) 1454-1461